Using the XeriSol Formulation Platform for Peptide Parenteral Drug Delivery

By | 21 November 2025
  • Presenting a non-aqueous, high concentration subcutaneous solution
  • Enabling room temperature stability
  • Showcasing excellent safety and toxicity profiles

NEW COMPANY